Supreme Court Narrows Criteria for Induced Patent Infringement in Hikma Case
The Supreme Court ruled that induced infringement claims require proof of active encouragement, not mere possibility.
Why it matters: This refines how patent holders may pursue claims against generic drug makers using skinny labels. It shapes strategies for patent enforcement and generic market entry.
- June 4, 2026: Supreme Court unanimously favors Hikma Pharmaceuticals.
- The case concerns Hikma's generic icosapent ethyl 'skinny label' excluding patented CV indication.
- Court clarified inducement requires plausible allegation of active encouragement, not mere possible interpretation.
- Justice Jackson emphasized focus on defendant's conduct, not third-party perceptions.
On June 4, 2026, the U.S. Supreme Court issued a unanimous ruling in Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc., clarifying the standards for induced patent infringement under 35 U.S.C. § 271(b). The Court held that Amarin failed to state a claim for active inducement because it did not plausibly allege Hikma took active steps to encourage infringement.
The dispute arose over icosapent ethyl, marketed by Amarin as Vascepa. The drug received FDA approval in 2012 for treating severe hypertriglyceridemia (SH indication) and in 2019 for reducing cardiovascular risk (CV indication). Hikma sought FDA approval for a generic using a 'skinny label,' including only the unpatented SH indication and excluding the patented CV indication.
The Court emphasized that patent holders must show more than just that third parties, such as doctors, could interpret a generic manufacturer's statements as encouragement to infringe. Justice Ketanji Brown Jackson wrote, "The proper question is whether Amarin plausibly alleged that Hikma actively encouraged infringing uses, not merely whether doctors could plausibly read the alleged statements as instructions to infringe."
This ruling affects pharmaceutical patent litigation by setting a higher bar for proving induced infringement claims against generic drug manufacturers that use 'skinny labels' to avoid patented uses. The decision signals that patent enforcement strategies must focus on demonstrating direct inducement actions by defendants.
By the numbers:
- June 4, 2026 — Date of the Supreme Court ruling
- 2012 — FDA approval of Vascepa for SH indication
- 2019 — FDA approval of Vascepa for CV indication